CA2460587A1 - Anti-pdgf antibodies and methods for producing engineered antibodies - Google Patents
Anti-pdgf antibodies and methods for producing engineered antibodies Download PDFInfo
- Publication number
- CA2460587A1 CA2460587A1 CA002460587A CA2460587A CA2460587A1 CA 2460587 A1 CA2460587 A1 CA 2460587A1 CA 002460587 A CA002460587 A CA 002460587A CA 2460587 A CA2460587 A CA 2460587A CA 2460587 A1 CA2460587 A1 CA 2460587A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- sequence
- library
- panel
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32354401P | 2001-09-20 | 2001-09-20 | |
| US32353701P | 2001-09-20 | 2001-09-20 | |
| US60/323,544 | 2001-09-20 | ||
| US60/323,537 | 2001-09-20 | ||
| US37999402P | 2002-05-13 | 2002-05-13 | |
| US60/379,980 | 2002-05-13 | ||
| PCT/US2002/030086 WO2003025019A1 (en) | 2001-09-20 | 2002-09-20 | Anti-pdgf antibodies and methods for producing engineered antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2460587A1 true CA2460587A1 (en) | 2003-03-27 |
Family
ID=27406282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002460587A Abandoned CA2460587A1 (en) | 2001-09-20 | 2002-09-20 | Anti-pdgf antibodies and methods for producing engineered antibodies |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1436329A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005512962A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2460587A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003025019A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7393648B2 (en) | 2001-12-03 | 2008-07-01 | Alexion Pharmaceuticals, Inc. | Hybrid antibodies |
| JP4723810B2 (ja) | 2001-12-03 | 2011-07-13 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | ハイブリッド抗体 |
| AU2003213022A1 (en) * | 2002-02-11 | 2003-09-22 | Alexion Pharmaceuticals, Inc. | Immunotherapeutics for biodefense |
| NZ542988A (en) * | 2003-04-23 | 2008-07-31 | Medarex Inc | Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies |
| NZ592039A (en) | 2003-08-27 | 2013-03-28 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| US7276585B2 (en) * | 2004-03-24 | 2007-10-02 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| WO2009129538A2 (en) * | 2008-04-18 | 2009-10-22 | Xencor, Inc. | Human equivalent monoclonal antibodies engineered from nonhuman variable regions |
| US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| US8642834B2 (en) | 2009-02-27 | 2014-02-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| JP2014519813A (ja) | 2011-04-25 | 2014-08-21 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用 |
| JO3787B1 (ar) | 2012-03-15 | 2021-01-31 | Janssen Biotech Inc | أجسام مضادة بشرية ضد cd27 و طرق و استخداماتها |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| SG11201408196RA (en) * | 2012-06-28 | 2015-03-30 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| WO2014052518A1 (en) | 2012-09-27 | 2014-04-03 | Allergan, Inc. | Biodegradable drug delivery systems for the sustained release of proteins |
| CN105188759A (zh) | 2013-03-14 | 2015-12-23 | 阿勒根公司 | 持续释放递送的组合物以及在制造过程中稳定蛋白质的方法 |
| SI4374873T1 (sl) | 2013-07-12 | 2026-01-30 | Astellas Us Llc | Sredstvo za uporabo pri zdravljenju ali preprečevanju oftalmoloških stanj |
| JP2019006732A (ja) * | 2017-06-27 | 2019-01-17 | 学校法人東京理科大学 | Mycタンパク質阻害剤、Mycタンパク質阻害方法、抗神経芽腫剤及びMycタンパク質の過剰発現を伴う疾患の治療方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5817310A (en) * | 1991-12-02 | 1998-10-06 | Cor Therapeutics, Inc. | Inhibitory immunoglobulin polypeptides to human PDGF beta receptor |
| US5976534A (en) * | 1993-02-25 | 1999-11-02 | Zymogenetics, Inc. | Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin |
| US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| AU1454199A (en) * | 1997-11-07 | 1999-05-31 | Massachusetts Institute Of Technology | Pdgf-mediated microvascular communication and methods of use thereof |
| WO1999029888A1 (en) * | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
-
2002
- 2002-09-20 JP JP2003528864A patent/JP2005512962A/ja not_active Withdrawn
- 2002-09-20 EP EP02775937A patent/EP1436329A4/en not_active Withdrawn
- 2002-09-20 WO PCT/US2002/030086 patent/WO2003025019A1/en not_active Ceased
- 2002-09-20 CA CA002460587A patent/CA2460587A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003025019A9 (en) | 2004-05-06 |
| JP2005512962A (ja) | 2005-05-12 |
| WO2003025019A8 (en) | 2004-04-01 |
| EP1436329A4 (en) | 2005-04-27 |
| WO2003025019A1 (en) | 2003-03-27 |
| EP1436329A1 (en) | 2004-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20030219839A1 (en) | Anti-PDGF antibodies and methods for producing engineered antibodies | |
| WO2003025019A1 (en) | Anti-pdgf antibodies and methods for producing engineered antibodies | |
| Schier et al. | Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection | |
| Chiu et al. | Engineering antibody therapeutics | |
| CN100480269C (zh) | 抗-血管内皮生长因子的抗体 | |
| JP5685274B2 (ja) | 結合タンパク質の混合物 | |
| CN101210050B (zh) | 抗-血管内皮生长因子的抗体 | |
| US20190031770A1 (en) | Intercalated single-chain variable fragments | |
| CN112646032B (zh) | 靶向bcma的具有人猴交叉的人源化单克隆抗体 | |
| JP2015524404A (ja) | 高度に保存された標的に対するラクダ科動物由来の配列を含む抗体 | |
| JP2010260845A (ja) | Mn結合および細胞接着中和活性を有するヒト抗体 | |
| JP7624478B2 (ja) | 癌治療において壊死を標的とするヒト化抗核抗体 | |
| EP2986640B1 (en) | Humanized antibody against interleukin-20 and treatment for inflammatory diseases | |
| US20060024666A1 (en) | Humanized antibodies against the venezuelan equine encephalitis virus | |
| CN110642947B (zh) | 抗人cd147的单克隆抗体、表达载体、细胞株及其应用 | |
| JP2006241026A (ja) | 抗体およびその利用 | |
| JP2026509245A (ja) | 抗体およびその使用 | |
| Padoa et al. | Engineered antibodies: A new tool for use in diabetes research | |
| AU2002341785A1 (en) | Anti-PDGF antibodies and methods for producing engineered antibodies | |
| EP1747015B1 (en) | Solution phase biopanning method using engineered decoy proteins | |
| JT George et al. | Section Review Biologicals & Immunologicals: Advances in antibody engineering | |
| US20260028399A1 (en) | Human-like target-binding proteins | |
| Putelli | Human antibody phage technology-isolation and characterization of monoclonal antibodies for the targeting of cancer and rheumatoid arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20080922 |